WO2007071092A1 - Sonde de glucose sanguin basée sur la spectroscopie de réflexion ou de transmission à des fréquences dans la région térahertzienne et au delà de la région térahertzienne - Google Patents
Sonde de glucose sanguin basée sur la spectroscopie de réflexion ou de transmission à des fréquences dans la région térahertzienne et au delà de la région térahertzienne Download PDFInfo
- Publication number
- WO2007071092A1 WO2007071092A1 PCT/CH2006/000716 CH2006000716W WO2007071092A1 WO 2007071092 A1 WO2007071092 A1 WO 2007071092A1 CH 2006000716 W CH2006000716 W CH 2006000716W WO 2007071092 A1 WO2007071092 A1 WO 2007071092A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- radiation
- blood
- terahertz
- frequencies
- liquid
- Prior art date
Links
- 239000008103 glucose Substances 0.000 title claims abstract description 36
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 35
- 239000008280 blood Substances 0.000 title claims abstract description 31
- 210000004369 blood Anatomy 0.000 title claims abstract description 30
- 238000001055 reflectance spectroscopy Methods 0.000 title description 2
- 238000002235 transmission spectroscopy Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 26
- 238000005259 measurement Methods 0.000 claims abstract description 19
- 238000001228 spectrum Methods 0.000 claims abstract description 15
- 239000012503 blood component Substances 0.000 claims abstract description 12
- 238000004458 analytical method Methods 0.000 claims abstract description 7
- 238000000985 reflectance spectrum Methods 0.000 claims abstract 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 31
- 230000005855 radiation Effects 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 229940109239 creatinine Drugs 0.000 claims description 2
- 230000000149 penetrating effect Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 8
- 238000001727 in vivo Methods 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 238000005070 sampling Methods 0.000 claims 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 210000003423 ankle Anatomy 0.000 claims 1
- 230000036760 body temperature Effects 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 claims 1
- 238000007405 data analysis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000005670 electromagnetic radiation Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000001788 irregular Effects 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 229940070376 protein Drugs 0.000 claims 1
- 210000000707 wrist Anatomy 0.000 claims 1
- 229960001031 glucose Drugs 0.000 description 31
- 235000001727 glucose Nutrition 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SKCKOFZKJLZSFA-UHFFFAOYSA-N L-Gulomethylit Natural products CC(O)C(O)C(O)C(O)CO SKCKOFZKJLZSFA-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 description 1
- 206010003504 Aspiration Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000001660 aspiration Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- -1 blood components Chemical compound 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 238000002044 microwave spectrum Methods 0.000 description 1
- 238000004476 mid-IR spectroscopy Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/0507—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves using microwaves or terahertz waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
- G01N21/3581—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using far infrared light; using Terahertz radiation
Definitions
- the invention relates to a non-invasive blood glucose sensor.
- Diabetes is a disease of growing consequence.
- a 2002 survey found that there were approximately 150 million diabetics in the world and it is estimated that there will be as many as 300 mil- lion by 2025. According to the American Diabetes Association, there are 16 million individuals in the U.S. who have diabetes.
- the FDA has approved only one truly non-invasive blood glucose monitoring device: The GlucoWatch G2 Biographer, manufactured by Cygnus Inc., approved to detect glu- cose level trends and track patterns in people with diabetes (it must be used along with conventional blood glucose monitoring of blood samples) .
- the device which looks like a wristwatch, pulls body fluid (interstitial fluid) from the skin using small electric currents . It can provide six measurements per hour for 13 hours.
- the Medtronic MiniMed also FDA approved, involves placing a subcutaneous sensor and then having this interface with a remote-readable 'black box' . This is not truly non-invasive, does not provide continuous measurements, works only for 3 days, and needs to be used with a docking station to read-out.
- Medtronic MiniMed uses a subcutaneously placed probe and runs for 3 days.
- a wristwatch-style device from Glucon Inc. uses tiny lasers that resonate with blood glucose to pro- prise ultrasound and give 24-hour measurements (photo-acoustic: origin Tel Aviv University: US patent granted Feb. 2005 for "the use of photoacoustic waves originating in the blood vessel to calculate the concentration of glucose in the blood vessel") . Also important is the location or measurement of blood volume to be able to measure concentration.
- Glucon "uses the acoustics e- lement to localize measured volume inside a blood vessel, as well as removing the influence of the outer layers of the skin, and the optics element provides the specificity to glucose by using several light wavelengths" . It claims to be as accurate as skin pricking, and is in the process of clinical trials and approval by the FDA. Launch ⁇ 2008, anticipated price >$1700.
- Hitachi has determined that it is possible to compute the level of blood sugar by measuring parameters such as the thermal energy generated by metabolic reactions, the level of oxygen saturation of hemoglobin, and blood flow.
- the device is undergoing clinical testing to support a premarket submission to the FDA and the Japan Ministry of Health, Labour and Welfare. Plans call for the device to go on sale in 2005, subject to regulatory approval .
- GlucoStats System (Singapore) have non-invasive IR probes: currently undergoing clinical trials.
- the present invention is characterized in that it combines the use of terahertz radiation and the use of infra-red radiation for detecting blood glucose and measuring its concentration by means of a multi-frequency radiation analysis, the radiation be- ing measured in reflected mode as well as potentially in transmitted and absorptive modes . It thus provides a more accurate reading than that possible with the use of any narrower frequency band such as IR or terahertz alone.
- terahertz radiation alone for detecting blood glucose is, rather surprisingly, not immediately identifiable in the EPO database. However this is not considered to be novel, since two companies have been identified which have targeted terahertz radiation as a means of detecting blood glucose.
- Spire 1 S quantum cascade laser device consists of hundreds of nanometer-thick gallium arsenide-based layers. Terahertz radia- tion has wavelengths that are longer than visible and infrared, but shorter than microwaves, and may be the only radiation source that can separate glucose from other substances .
- Spire ' s terahertz quantum cascade laser instrument eliminates the need to draw blood samples by finger pricking . Thus , Spire ' s painless, non-invasive method of glucose detection using terahertz radiation may encourage diabetics to monitor their blood sugar levels more frequently' .
- Spire will synthesize a number of phantom samples containing various glucose concentrations, as well as samples containing potentially competing species such as sucrose and fructose, and measure their optical characteristics with terahertz radiation.
- the terahertz measurements will be carried out with the assistance of Dr. Tatiana Globus, Research Associate Professor in the Department of Electrical and Computer Engineering at the University of Virginia, at the Brookhaven National Laboratory in Upton, New York. Terahertz devices will be incorporated into a demonstration glucose monitoring instrument during Phase II of the development project' .
- Teraview (Cambridge, UK) also has aspira- tions towards using terahertz radiation for non-invasive blood glucose sensing, but it has made no recent announcements (since 2002) on this. Teraview has some 31 patents, but none specifically mentions x blood' or 'glucose' .
- That blood glucose has a distinctive IR spectrum is known from recent work in Fourier-transform infrared (FTIR) spectroscopy by Yaochun Shen at the Cavendish Laboratories, University of Cambridge .
- FTIR Fourier-transform infrared
- the project developed infrared assays for the biomedical analysis of blood samples by mid-IR spectroscopy to determine blood glucose, cholesterol, urea, total protein, triglycerides and creatinine, but not similar analysis means in- corporating teraHertz measurements.
- Infra-red light emitting diodes capable of emitting different frequencies of infra-red radiation.
- Terahertz light-emitting-diodes capable of emitting different frequencies of terahertz radiation.
- Terahertz emission is capable of penetrating skin non-invasively to register subcutaneous structures.
- the advantage utilized in the present invention is a small, cheap emitter device (LED type) , hitherto not achieved: it is tuneable, by magnetic field, and thus able to scan across a range of frequencies .
- LED type emitter device
- 4.) The knowledge of the 'signature' spectrum on glucose and other components of interest in the terahertz region and how these can be distinguished from other blood component spectra.
- Multi-frequency scanning analysis technology which is capable of being trained to look for 'signatures' of specific compounds in the IR-to-microwave spectrum (and beyond) . This has been used in the IR and the microwave region for various uses including the detection of CJD prions in blood supplies, and in the IR to UV region for imaging historic documents such as the Dead Sea Scrolls. Multi-frequency scanning in the terahertz region (alone) has been used for explosives and prohibited substances detection: it has not hitherto been used in combination with other non-terahertz frequencies for blood glucose or other blood component detection.
- the technology involves the testing of samples with different frequencies / wavelengths of radiation, measuring (or imaging) the reflected signal digitally, and then combining these digital data to provide a composite where the presence or absence of a signal is dependant upon data taken at more than one frequency / wavelength.
- Patentable features claimed are the particular components, frequencies and algorithms used.
- This method can be made into a hand-held home-use product containing at least IR and terahertz LED emitters, a reflective multi-frequency sensor, and appropriate detection software.
- a device can in principle be used for continuous use if appropriately configured as a wristwatch- or similar type device. Such a device could be used in conjunction with other monitoring systems .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Emergency Medicine (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
L’invention concerne une méthode pour mesurer la concentration de composants sanguins tel que, mais non limités au glucose sanguin de manière non envahissante qui consiste à employer la mesure et l’analyse de spectres qui incluent, mais non limités aux spectres de réflectance dans au moins les régions infrarouge et térahertzienne du spectre électromagnétique, dans chaque cas dans une fourchette de fréquences, ou à au moins plusieurs fréquences significatives.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75206205P | 2005-12-21 | 2005-12-21 | |
| US60/752,062 | 2005-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2007071092A1 true WO2007071092A1 (fr) | 2007-06-28 |
Family
ID=37770818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CH2006/000716 WO2007071092A1 (fr) | 2005-12-21 | 2006-12-20 | Sonde de glucose sanguin basée sur la spectroscopie de réflexion ou de transmission à des fréquences dans la région térahertzienne et au delà de la région térahertzienne |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2007071092A1 (fr) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104873207A (zh) * | 2015-05-15 | 2015-09-02 | 深圳市一体太糖科技有限公司 | 一种太赫兹连续血糖测量系统 |
| CN105486731A (zh) * | 2015-08-12 | 2016-04-13 | 成都市亿泰科技有限公司 | 基于太赫兹增强的无创血糖检测探头 |
| US10568584B2 (en) | 2015-11-30 | 2020-02-25 | Samsung Electronics Co., Ltd. | Apparatus for estimating blood component level using spectrum analysis |
| US12017216B2 (en) | 2020-01-10 | 2024-06-25 | Roche Diagnostics Operations, Inc. | Method and laboratory system to process a laboratory carrier based on a feature of a test liquid in the laboratory carrier |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5313941A (en) * | 1993-01-28 | 1994-05-24 | Braig James R | Noninvasive pulsed infrared spectrophotometer |
| US5452716A (en) * | 1992-02-25 | 1995-09-26 | Novo Nordisk A/S | Method and device for in vivo measuring the concentration of a substance in the blood |
| GB2360842A (en) * | 2000-03-31 | 2001-10-03 | Toshiba Res Europ Ltd | Investigating a sample using electromagnetic radiation |
| WO2003069318A2 (fr) * | 2002-02-15 | 2003-08-21 | Teraview Limited | Analyseur et procede correspondant |
-
2006
- 2006-12-20 WO PCT/CH2006/000716 patent/WO2007071092A1/fr active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5452716A (en) * | 1992-02-25 | 1995-09-26 | Novo Nordisk A/S | Method and device for in vivo measuring the concentration of a substance in the blood |
| US5313941A (en) * | 1993-01-28 | 1994-05-24 | Braig James R | Noninvasive pulsed infrared spectrophotometer |
| GB2360842A (en) * | 2000-03-31 | 2001-10-03 | Toshiba Res Europ Ltd | Investigating a sample using electromagnetic radiation |
| WO2003069318A2 (fr) * | 2002-02-15 | 2003-08-21 | Teraview Limited | Analyseur et procede correspondant |
Non-Patent Citations (6)
| Title |
|---|
| COMPOUND SEMICONDUCTOR.NET: "Spire hopes to ease diabetics' lives", 24 August 2004 (2004-08-24), XP002425058, Retrieved from the Internet <URL:http://compoundsemiconductor.net/articles/news/8/8/19/1> [retrieved on 20070315] * |
| GILWON YOON ET AL: "Reagentless/non-invasive diagnosis of blood substances", LASERS AND ELECTRO-OPTICS, 2001. CLEO/PACIFIC RIM 2001. THE 4TH PACIFIC RIM CONFERENCE ON 15-19 JULY 2001, PISCATAWAY, NJ, USA,IEEE, vol. 1, 15 July 2001 (2001-07-15), pages I226 - I227, XP010566095 * |
| MASAKAZU HINENO: "INFRARED SPECTRA AND NORMAL VIBRATIONS OF BETA-D-GLUCOPYRANOSE", CARBOHYDRATE RESEARCH, vol. 56, 1977, Amsterdam, pages 219 - 227, XP002425060 * |
| NISHIZAWA J -I ET AL: "Terahertz wave generation and Raman amplification in semiconductors", PROCEEDINGS OF THE SPIE - THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING SPIE-INT. SOC. OPT. ENG USA, vol. 5445, no. 1, 2004, pages 8 - 13, XP002425059, ISSN: 0277-786X * |
| VONACH R ET AL: "Application of mid-infrared transmission spectrometry to the direct determination of glucose in whole blood", APPL SPECTROSC; APPLIED SPECTROSCOPY JUN 1998 SOC FOR APPLIED SPECTROSCOPY, FREDERICK, MD, USA, vol. 52, no. 6, June 1998 (1998-06-01), pages 820 - 822, XP009080696 * |
| YOSHINAGA H ET AL: "Far Infrared Spectrograph for Use From the Prism Spectral Region to About 1 mm Wavelength", JOURNAL OF THE OPTICAL SOCIETY OF AMERICA USA, vol. 48, no. 5, May 1958 (1958-05-01), pages 315 - 323, XP009080573 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104873207A (zh) * | 2015-05-15 | 2015-09-02 | 深圳市一体太糖科技有限公司 | 一种太赫兹连续血糖测量系统 |
| CN105486731A (zh) * | 2015-08-12 | 2016-04-13 | 成都市亿泰科技有限公司 | 基于太赫兹增强的无创血糖检测探头 |
| US10568584B2 (en) | 2015-11-30 | 2020-02-25 | Samsung Electronics Co., Ltd. | Apparatus for estimating blood component level using spectrum analysis |
| US12017216B2 (en) | 2020-01-10 | 2024-06-25 | Roche Diagnostics Operations, Inc. | Method and laboratory system to process a laboratory carrier based on a feature of a test liquid in the laboratory carrier |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Villena Gonzales et al. | The progress of glucose monitoring—A review of invasive to minimally and non-invasive techniques, devices and sensors | |
| US20050054907A1 (en) | Highly portable and wearable blood analyte measurement system | |
| Khalil | Spectroscopic and clinical aspects of noninvasive glucose measurements | |
| Yadav et al. | Prospects and limitations of non-invasive blood glucose monitoring using near-infrared spectroscopy | |
| CN101917899B (zh) | 用于测定分析物浓度的光学传感器 | |
| CN1325015C (zh) | 通过组织的光学特性的葡萄糖非侵入性测量 | |
| Yamakoshi et al. | Pulse glucometry: a new approach for noninvasive blood glucose measurement using instantaneous differential near-infrared spectrophotometry | |
| CN1321610C (zh) | 通过组织性能进行的组织分析物的间接测量 | |
| US7729734B2 (en) | Non-invasive biothermophotonic sensor for blood glucose monitoring | |
| JP2021037321A (ja) | 血中物質濃度測定装置及び導光部 | |
| US8406839B2 (en) | Method and apparatus for determining blood analytes | |
| US20180310880A1 (en) | Methods for Reducing Noise in Optical Biological Sensors | |
| US10499839B1 (en) | Optimized biophotonic sensors | |
| KR100775669B1 (ko) | 팔목 휴대용 무채혈 혈당측정 장치 | |
| WO2004081524A2 (fr) | Procede de pretraitement de donnees selon les sites de mesure pour etalonnage et prediction robustes | |
| Losoya-Leal et al. | State of the art and new perspectives in non-invasive glucose sensors | |
| US20230277063A1 (en) | Wearable spectrometer for biomolecule interrogation in biological tissue | |
| US20210275061A1 (en) | Human gas sensing glucose monitoring and ketone fluctuation detection device | |
| US20220354398A1 (en) | Device, system and method for non-invasive monitoring of physiological measurements | |
| WO2012136982A1 (fr) | Dispositif et procédé pour la détection d'analytes sanguins | |
| WO2007071092A1 (fr) | Sonde de glucose sanguin basée sur la spectroscopie de réflexion ou de transmission à des fréquences dans la région térahertzienne et au delà de la région térahertzienne | |
| Priyoti et al. | Non-invasive blood glucose measurement using near infra-red spectroscopy | |
| Ogunsanya et al. | Design and Development of a Non-invasive Glucometer System. | |
| Bai et al. | Assessing and advancing technology for the noninvasive measurement of clinical glucose | |
| Luong et al. | Research and design a non-invasive blood glucose measuring module |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06817766 Country of ref document: EP Kind code of ref document: A1 |